肝移植中门静脉血栓的处理经验

目的 探讨肝移植术中门静脉血栓的几种处理方法及其疗效.方法 回顾性分析773例次肝移植临床资料.773例中,107例病人有门静脉血栓,其中59例Ⅰ级;33例Ⅱ级;12例Ⅲ级;3例Ⅳ级.Ⅰ、Ⅱ级组行血栓切除或取栓术;Ⅲ级采用取栓术或肠系膜上静脉架桥的方式重建供肝门静脉;对Ⅳ级采用改良门腔静脉半转位术和门静脉胃冠状静脉吻合重建供肝门静脉.结果 Ⅰ、Ⅱ级组移植肝功能恢复良好,围手术期病死率为4.3%.Ⅲ级取栓组5例肝功能恢复良好,围手术期无死亡.静脉架桥组7例中有2例肝功能恢复不佳,围手术期病死率为28.6%.Ⅳ级组肝功能恢复良好,围手术期无死亡.结论 门静脉血栓已非肝移植禁忌证,根据血栓的不同情况采取合理的手术方式重建门脉系统可以获得良好的治疗效果.     

肝硬化伴门静脉血栓患者行肝移植术的处理

目的 分析合并门静脉血栓的肝硬化患者肝移植术中及术后的处理方法和疗效.方法 回顾分析2005年10月至2007年3月我院完成的161例良性终末期肝病患者的临床资料,比较门静脉血栓发生率,不同级血栓手术情况和生存率.结果 161例患者之中共有15例患者合并有门静脉血栓,其中1级8例,2级4例,3级3例.脾切除史中发生P...     

肝移植加腔门半转位术三例报告

弥漫性门静脉血栓形成在等待肝移植的患者中约占2．1％-26％。目前，肝移植加腔门半转位术（CPHT）已经成为治疗该类患者的有效方法㈦。本文回顾性分析我中心3例肝移植加腔门半转位术后的随访情况，现报告如下。     

术前门静脉血栓对活体肝移植预后的影响

目的 探讨术前门静脉血栓对活体肝移植的影响.方法 回顾性分析天津市第一中心医院2007至2011年完成的99例成人间活体肝移植患者,根据术前是否有门静脉血栓分为2组,血栓组26例,无血栓组73例.比较2组的术前危险因素及门静脉血栓对活体肝移植手术和术后患者预后的影响.结果 26例门静脉血栓患者Ⅰ级血栓23例,Ⅱ级血栓3例.肝移植术前的脾切除是发生门静脉血栓的独立危险因素(x2 =10.211,P=0.001).术前门静脉血栓会延长手术的无肝期(Z=-2.430,P=0.015),但2组患者术后并发症发生率(x2=0.326,P=0.568)及死亡率均无统计学差异,而且对患者的1年生存率和3年生存率均无影响(x2=0.505,P =0.477).结论 对于活体肝移植合并Ⅰ级或Ⅱ级门静脉血栓的患者,通过合理的术中处理及术后预防,门静脉血栓不会影响患者的预后.但门静脉血栓增加了一定的手术难度,需要详尽的术前评估和仔细的术中操作.     

肝移植术中门静脉血栓和瘤栓的处理

目的 探讨肝移植时门静脉血栓和瘤栓的处理方法和临床效果.方法 2000年8月至2004年底我院施行的150例肝移植患者中5例为肝硬化伴门静脉血栓形成,21例为肝癌伴门静脉瘤栓及/或血栓形成,共26例.这些病例在术中清除了门静脉内的栓子,3例又行门静脉壁部分切除及低位门静脉对端吻合术,1例行门腔静脉半转位吻合术.结果 26例中1例术后门静脉又再发血栓形成.21例肝癌合并门静脉瘤栓者,术后近期死亡3例,分别死于：门静脉继发性血栓形成,移植肝原发性无功能和多器官衰竭.18例得到长期随访,术后1、2、3年生存率分别为：66.7%,38.9%,27.8%.结论 肝移植时受体门静脉合并血栓/瘤栓者在清除栓子后再行肝移植仍然可取得较好的疗效.     

门静脉血栓的肝移植术中处理

目的 探讨门静脉血栓(PVT)的肝移植术中外科处理方法及其效果.方法 肝移植患者2508例,共行肝移植2614次,其中253例术前并发PVT.并发PVT者的Yerdel分级为,Ⅰ级者104例,Ⅱ级者114例,Ⅲ级者29例,Ⅳ级者6例.根据具体情况对并发Ⅰ、Ⅱ级PVT者施行静脉血栓切除术、外翻血栓切除术或外翻式门静脉内膜剥脱切除术;并发Ⅲ级PVT者,18例行外翻式门静脉内膜剥脱切除术,11例行外翻血栓切除术;并发Ⅳ级PVT者行外翻式门静脉内膜剥脱切除术.结果 218例并发Ⅰ、Ⅱ级PVT者中,32例行静脉血栓切除术,52例行外翻血栓切除术,134例行外翻式门静脉内膜剥脱切除术,均获得成功.29例并发Ⅲ级PVT者中,18例行外翻式门静脉内膜剥脱切除术,均获得成功;11例行外翻血栓切除术,其中5例获得成功,6例失败.6例并发Ⅳ级PVT者中,3例行外翻式门静脉内膜剥脱切除术,获得成功,3例取栓失败.253例并发PVT者肝移植术后6个月的存活率为93.7%,与同期无PVT的肝移植患者相比较(94.4%),差异无统计学意义(P>0.05).结论 并发PVT者可接受肝移植,术中应根据PVT的Yerdel分级情况,采取适合的外科处理方式.     

存在门静脉血栓及癌栓的肝癌患者的肝移植

目的　探讨存在门静脉血栓或癌栓的肝癌患者进行肝移植的处理要点。方法　对10例存在门静脉血栓或癌栓的肝癌患者施行原位肝移植术,术前常规准备供者的髂静脉,供肝保留较长的门静脉;术中注意取尽受者门静脉内的血栓或癌栓,门静脉壁存在水肿、增厚、变硬者,尽可能切除这段门静脉;9例行低位门静脉对端吻合,1例行门静脉下腔静脉的对端吻合;术后根据患者的凝血功能状态决定是否进行抗凝治疗。结果　1例术后第6 d发生门静脉血栓形成,溶栓术后因腹腔内出血、失血性休克死亡;另9例术后门静脉血流通畅,随访2~31个月,其中1例术后2个月死于感染,4例术后7、12、13、25个月肿瘤复发,其余4例无肿瘤复发。结论　术前存在门静脉血栓或癌栓的肝癌患者,只要处理得当,采用肝移植治疗可以取得较好结果。     

肝移植中基于门静脉重建方案的门静脉血栓分类及处理策略

门静脉血栓（PVT）的处理目前仍然是肝移植手术技术方面的一大挑战,复杂的PVT需要根据血栓的范围、机化及其与血管壁的粘连程度、侧支血管的代偿分流情况等,选择最适合的处理方案,以达到最佳的疗效。本文提出了一种基于门静脉取栓后血流再通情况和门静脉重建方案的PVT分类方法, 并进一步分析了3类PVT相应的处理方案。采用基于门静脉重建方案的PVT分类,对PVT患者肝移植的预后具有较为准确的评估价值,可以尝试在临床治疗中推广应用。     

基于门静脉重建方案的肝移植围术期门静脉血栓处理策略

正门静脉血栓(portal vein thrombosis,PVT)曾是肝移植的相对甚至绝对禁忌证。广泛或复杂的PVT往往需采取非生理性、非解剖性途径,重建移植肝的门静脉入肝血流,技术复杂、并发症发生多,处理不当可能导致灾难性后果。PVT的处理是目前肝移植手术技术的一大挑战。Hibi等[1]对174例PVT病人肝移植的分析显示,无论Yerdel分级[2]如何,只要能达到常规的端端重建,术后移植肝的功能恢复及     

Surgical strategies for liver transplantation in the case of portal vein thrombosis--current role of cavoportal hemitransposition and renoportal anastomosis

Portal vein thrombosis (PVT), a common complication of end stage liver disease, is no longer considered a definite contraindication for liver transplantation (LTx). The clinical decision to perform an LTx in the case of PVT depends on the degree of PVT and the experience of the surgeon. Eversion thromboendovenectomy was suggested by most authors as the surgical technique of choice for PVT grade 1, 2, and 3. If PVT obstructs more extended parts of the porto-mesenteric venous circulation, surgical options would include different types of venous jump graft reconstructions or arterialization of the portal vein. Combined liver and small bowel transplantation is another possible alternative. Cavoportal hemitransposition (CPHT) and renoportal anastomosis (RPA) were recently particularly advocated as creative surgical strategies in case of diffuse PVT. In this work, we focus on CPHT and RPA surgical techniques during LTx, which attempts to secure the portal flow to the liver graft in case of pre-existent diffuse PVT. We provide a review of all reported clinical experience at international clinical centers using these techniques. According to our meta-analysis a total of 15 studies were published on this topic between 1996 and 2005. In summary, a total of 56 orthotopic LTx have been performed in 53 patients (28 men, 25 women) combined with either CPHT or RPA, for the purpose of providing the donor graft with adequate inflow. Mean age was 44 yr including two patients who were infants, with the youngest recipient being two yr old. Main indications for LTx were liver cirrhosis caused by viral hepatitis, alcoholic cirrhosis and cryptogenic cirrhosis. CPHT was performed in 46 cases, and RPA in 10 cases. Thirty-five of 53 patients (66%) had surgery previous to LTx. Of these, 13 patients (37%) [corrected] presented with a history of other previous surgical procedures for decompression of portal hypertension or treatment of associated complications (portocaval shunts, splenectomy, etc). Ascites, renal dysfunction, lower extremity and torso edema and variceal bleeding were dominant post-operative complications after CPHT or RPA noted in 22 cases (41.5%), 18 cases (34%), 17 cases (32%) and 13 cases (24.5%) respectively. Patients' follow-up ranged from two to 48 months. Thirty nine of 53 patients [corrected] (74%) survived [corrected] and 14 patients died (26%) [corrected] during the course of observation. Based on the literature, we conclude that the ideal technique to overcome PVT during LTx is still controversial. Short-term follow-up results of both methods are promising, however, long-term results are unknown at present. Furthermore, clinical follow-up and basic experimental work is required to evaluate the influence of systemic venous inflow to the liver graft with respect to long-term liver function and liver regeneration.     

合并门静脉血栓形成的肝细胞癌肝移植12例分析

目的探讨合并门静脉血栓形成(PVT)的肝细胞癌肝移植手术疗效、手术技巧及围手术期处理。方法回顾性分析中山大学附属第三医院自2003年10月至2005年6月12例合并PVT的肝细胞癌肝移植临床及随访情况。结果术后随访8d至36个月,中位时间19.5个月。术后第12天、第21天、第30天各死亡1例,死于肺部感染、多器官功能衰竭。随访期间死亡1例(术后第15个月死于肝癌复发)。目前存活8例,其中7例已经无瘤生存13、14、24、24、25、28、30个月,1例带瘤存活36个月。12例病人1年累积存活率75.0%。1例病人肝移植术后2个月吻合口局部PVT复发,目前已经存活30个月。结论合并PVT的肝细胞癌肝移植者预后良好,合理的手术技巧和恰当的术后处理可以避免术后PVT复发。     

Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity

Doenecke A, Tsui T-Y, Zuelke C, Scherer MN, Schnitzbauer AA, Schlitt H-J, Obed A. Pre-existent portal vein thrombosis in liver transplantation: influence of pre-operative disease severity.
Clin Transplant 2010: 24: 48–55. © 2009 John Wiley & Sons A/S.   Abstract: 
Background:  Portal vein thrombosis (PVT) is a surgical challenge in liver transplantation (LTx). In contrast to LTx in decompensated liver disease, which are associated with a higher morbidity and mortality, PVT influence on outcome is still under debate. To evaluate this influence at different stages of liver decompensation, we compared the outcome of patients suffering from PVT to patients with patent portal vein within different score ranges.
Methods:  We included 193 LTx (24 with PVT) in our study, transplanted between 2004 and 2007 at our institution. Patients were divided into four Model of End-Stage Liver Disease (MELD) score groups, and outcome was compared between PVT- and non-PVT patients.
Results:  In non-decompensated liver disease (MELD <15), we found a significantly decreased survival in patients suffering from PVT (one-yr survival 57% vs. 89%). By contrast, MELD score >15 (decompensated liver disease) leads to an equal or even better survival in PVT-patients compared with patients without PVT (one-yr survival 91% vs.75%), with an only slightly increased morbidity.
Conclusion:  Outcome in patients with PVT seems to be dependent on pre-operative disease severity. In contrast to compensated liver disease, no influence of PVT on outcome could be found in decompensated liver disease, and should therefore not be considered as a contraindication in LTx.     

Eversion thromboendovenectomy in organized portal vein thrombosis during liver transplantation

Portal thrombosis is no longer considered a contraindication for transplantation because of the technical experience acquired in the field of liver transplantation and the development of various surgical techniques. All the same, the results obtained in portal thrombosis patients are at times suboptimal, and the surgical technique used (thromboendovenectomy or veno-venous bypass) is also controversial. Between May 1988 and December 2001, 455 liver transplants were performed, of which 32 (7%) presented portal vein thrombosis. Of these, eight belonged to the first 227 transplants (group I), and 24 to the other 228 (group II). Of the 32 cases with portal thrombosis, 20 (62%) were type Ib, seven (22%) type II/III and five (16%) type IV. Twenty-two were males (69%), with a mean age of 50 yr (range: 30-70 yr); the thrombosis in all cases developed over a cirrhotic liver: 15 cases of an ethanolic origin, 11 because of hepatitis C virus, two cases of autoimmune aetiology, one case of primary biliary cirrhosis, one case because of hepatitis B virus and two cases of a cryptogenic origin. Five cases had a history of surgical treatment for portal hypertension. The surgical method in all cases consisted of an eversion thromboendovenectomy (ETEV) under direct visual guidance, with occlusion of the portal flow using a Fogarty balloon. Once re-canalization was achieved, we performed local heparinization and end-to-end portal anastomosis. In no case was systemic post-operative heparinization performed. In the 32 cases in which thrombectomy was attempted it was achieved in 31 of them (96%), failing only in a case of type IV thrombosis, which was resolved by portal arterialization. Of the 31 successful cases, only one with type IV thrombosis re-thrombosed. The 5-yr survival rate of the patients in the series was 69%, with 10 patients dying, of whom only two from causes related to the thrombosis and the thrombosis treatment, both with type IV thrombosis. The ideal treatment for portal thrombosis during liver transplantation is controversial and depends on its extension and the experience of the surgeon. In our experience, ETEV resolves most thromboses (types I, II and III), but management of type IV, which occasionally can be treated with this technique, may require more complex procedures such as bypass, portal arterialization or cavoportal haemitransposition.     

肝移植术中复杂门静脉机化血栓的处理

目的：探讨存在复杂门静脉机化血栓者肝移植术中门静脉的处理要点。方法：为17例机化血栓超过门静脉内径50％的患者施行肝移植，术中9例在切除血栓段门静脉或取栓后，将受者的门静脉与供肝门静脉行端端吻合；5例将供肝门静脉与受者的曲张冠状静脉行端侧吻合；1例切除闭塞段门静脉，利用供者的髂静脉于供肝门静脉与受者肠系膜上静脉间搭桥；1例供肝门静脉与受者的胆总管前曲张静脉行端侧吻合；1例采用供者的髂静脉在供肝门静脉和受者的脾门旁曲张静脉间搭桥，行端侧吻合。结果：17例患者，死亡2例，1例死于感染，1例死于肝动脉出血，但此2例患者的门静脉血流一直通畅。存活的15例随访2～12个月，其中1例术后因门静脉血流量不足，而行二次肝移植，在缝扎分流的侧支后，门静脉血流恢复正常，其他患者的门静脉血流均通畅。结论：存在复杂门静脉机化血栓时首选栓塞段门静脉切除或取栓后门静脉重建，不能取栓或取栓后血流量不足时，可改行供肝门静脉与受者曲张内脏静脉的端侧吻合，也可取得较好效果。     

Outcome of modified portal vein anastomosis for recipients with portal vein thrombosis or stenosis before living donor liver transplantation

Background

Portal vein thrombosis (PVT) or stenosis (PVS) often requires challenging techniques for reconstruction in living donor liver transplantation (LDLT).

Materials and Methods

A total of 57 LDLTs were performed between October 1996 and December 2010. There were 16 cases (28%) with PVT/PVS that underwent modified portal vein anastomosis (m-PVa). The m-PVa techniques were classified into 3 groups: patch graft (Type-1), interposition graft (Type-2), and using huge shunt vessels (Type-3). The reconstruction patterns were evaluated with regard to age, graft vessels, PV flow, and complication rate.

Results

The m-PVas were Type-1 in 10 cases, Type-2 in 3 cases, and Type-3 in 3 cases. The vessel graft in Type-1 was the inferior mesenteric vein (IMV) in 8 and the jugular vein in 2 cases, whereas the vessel graft in Type-2 was IMV in 2 and the saphenous vein in 1 case; in Type-3, the vessel grafts were renoportal, gonadal-portal, and coronary-portal anastomoses, respectively. The postoperative PV flow was sufficient in all types and slightly higher in Type-3. The postoperative complications occurred in 20% of the patients who underwent Type-1, in 33% who underwent Type-2, and in 0% who underwent Type-3.

Conclusion

The m-PVa was effective to overcome the surgical difficulty during transplantation. Pretransplant planning for the selection of the type of reconstruction is important for recipients with PVT/PVS.     

肝移植围手术期门静脉血栓的处理

目的 探讨肝移植围手术期门静脉血栓（PVT）的处理。方法 回顾性分析中国医科大学附属第一医院1995年5月至2008年6月实施的194例肝移植病人临床资料,术前存在PVT 24例,其中Ⅰ级12例,Ⅱ级9例,Ⅲ级2例,Ⅳ级1例。术中采取不同门静脉重建方式,结扎术前存在的门腔分流和粗大的侧支循环。术后根据凝血酶原时间（PT）,应用普通肝素或低分子质量肝素预防性抗凝。术中、术后应用多普勒超声监测门静脉血供。结果 术后PVT发生率2.58%（5/194）。1例PVT经外科门静脉取栓、重新吻合治愈,3例置管溶栓、支架植入治愈,另1例仅表现肝功能轻度异常,未特殊处理。与PVT相关病死率为0。其余病例随访6~ 104个月,未见PVT。结论 理想的门静脉重建方式、结扎门腔存在的分流和术后有效的抗凝可以减少PVT的发生,多普勒超声监测能早期发现PVT,挽救移植物,避免再移植。